Skip to Main Content

Paper Details

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Am J Hematol
27
2019
Author NameAffiliation
Jennifer DunlapOregon Health & Science University
Jessica LeonardKnight Cancer Institute, Oregon Health & Science University
Jessica LeonardOregon Health & Science University
Mara RosenbergKnight Cancer Institute, Oregon Health & Science University
Mara RosenbergKnight Cancer Institute, Oregon Health & Science University
Rachel CookKnight Cancer Institute, Oregon Health & Science University
Rachel CookOregon Health & Science University
Richard D PressOregon Health & Science University
Richard D PressKnight Cancer Institute, Oregon Health & Science University
Guang FanOregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerOregon Health & Science University
Brian J DrukerHoward Hughes Medical Institute
Elie TraerKnight Cancer Institute, Oregon Health & Science University
Elie TraerOregon Health & Science University
  • 1 - 15

Datasets

Release 1.2